Harvard Bioscience, Inc.
HBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $20,591 | $20,450 | $21,774 | $24,556 |
| % Growth | 0.7% | -6.1% | -11.3% | – |
| Cost of Goods Sold | $8,570 | $10,079 | $9,590 | $10,545 |
| Gross Profit | $12,021 | $10,371 | $12,184 | $14,011 |
| % Margin | 58.4% | 50.7% | 56% | 57.1% |
| R&D Expenses | $2,132 | $2,189 | $2,321 | $2,328 |
| G&A Expenses | $4,176 | $4,262 | $5,185 | $4,803 |
| SG&A Expenses | $8,789 | $8,801 | $10,156 | $10,198 |
| Sales & Mktg Exp. | $4,613 | $4,539 | $4,971 | $5,395 |
| Other Operating Expenses | $903 | $200 | $49,375 | $1,474 |
| Operating Expenses | $11,824 | $11,190 | $61,852 | $14,000 |
| Operating Income | $197 | -$819 | -$49,668 | $11 |
| % Margin | 1% | -4% | -228.1% | 0% |
| Other Income/Exp. Net | -$1,331 | -$1,435 | -$1,126 | $579 |
| Pre-Tax Income | -$1,134 | -$2,254 | -$50,794 | $590 |
| Tax Expense | $97 | $28 | -$454 | $572 |
| Net Income | -$1,231 | -$2,282 | -$50,340 | $18 |
| % Margin | -6% | -11.2% | -231.2% | 0.1% |
| EPS | -0.03 | -0.052 | -1.14 | 0 |
| % Growth | 41.7% | 95.5% | -285,100% | – |
| EPS Diluted | -0.03 | -0.052 | -1.14 | 0 |
| Weighted Avg Shares Out | 44,556 | 44,303 | 44,096 | 43,538 |
| Weighted Avg Shares Out Dil | 44,556 | 44,303 | 44,096 | 43,538 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $966 | $791 | $802 | $853 |
| Depreciation & Amortization | $1,324 | $1,618 | $1,655 | $1,760 |
| EBITDA | $1,156 | $155 | -$48,337 | $3,203 |
| % Margin | 5.6% | 0.8% | -222% | 13% |